Clinical evaluation of a new generation membrane oxygenator: a prospective randomized study

Area of Science:

• Cardiovascular Surgery
• Biomedical Engineering
• Medical Devices

Background:

• The Spiral Gold is a new hollow-fibre membrane oxygenator.
• Evaluating its clinical performance is crucial for cardiopulmonary bypass procedures.

Purpose of the Study:

• To assess the operational performance of the Spiral Gold oxygenator.
• To compare the Spiral Gold with the existing Univox Gold membrane oxygenator in clinical settings.

Main Methods:

• A randomized controlled trial involving 26 patients undergoing coronary artery bypass grafting.
• Patients were divided into two groups: Spiral Gold (n=13) and Univox Gold (n=13).
• Key parameters evaluated included hematological, hemodynamic, oxygenator performance, and perioperative outcomes.

Main Results:

• The Spiral Gold group exhibited a significantly lower pressure drop during cardiopulmonary bypass (26.9 vs 46.7 mmHg).
• Plasma free hemoglobin levels were significantly lower in the Spiral Gold group, indicating reduced hemolysis.
• Higher heat exchange coefficients were observed in the Spiral Gold group during rewarming (0.59 vs 0.36).

Conclusions:

• The Spiral Gold oxygenator demonstrates superior performance compared to the Univox Gold.
• It offers improved oxygen transfer efficiency and reduced rates of blood cell damage.
• These findings suggest the Spiral Gold is a promising advancement in membrane oxygenation technology.